Author name: Claritas Rx

The treatment landscape for rare diseases is rapidly evolving, offering both opportunities and challenges for biopharma professionals and patient service teams. With over 7,000 known rare diseases affecting an estimated 300 million people globally, the need for innovation and collaboration has never been greater. Yet, rare diseases are often underfunded, understudied, and misunderstood, leaving many […]

Rare diseases affect approximately 30 million people in the United States, yet the path to diagnosing and treating these conditions remains notoriously complex. With small patient populations, high treatment costs, and the necessity for robust engagement strategies, the rare disease sector is filled with challenges. For biopharma professionals, the focus remains on finding innovative ways

The landscape of rare diseases is evolving rapidly, with groundbreaking cell and gene therapies leading the way. These innovative treatments offer hope to patients with diseases previously considered untreatable. However, with innovation comes complexity—bringing these therapies to market isn’t just about scientific breakthroughs but also navigating unique market access challenges. This blog dives into the

Understanding how data and technology intersect with patient support services is essential for teams striving to improve patient outcomes. At the recent Access Patient Support Services Congress, a panel discussion titled “Optimizing Patient Services — Leveraging Data and Technology to Improve Patient Programs” gathered experienced leaders in patient services to share their valuable insights on

Eli Lilly has consistently demonstrated its dedication to precision oncology, and its latest acquisition is a testament to that commitment. The biopharma giant announced a $2.5 billion deal with Scorpion Therapeutics to acquire an experimental cancer drug targeting PI3Kα mutations. This strategic move positions Lilly to further advance its oncology portfolio and address significant unmet

Market access in the biopharma industry goes beyond delivering innovative therapies—it’s about ensuring patients receive timely and seamless access to those treatments. Two key metrics, fill rate and time-to-fill, have emerged as essential benchmarks for assessing operational efficiency, improving patient access, and aligning with strategic goals. But how can biopharma professionals effectively use these metrics

The biopharmaceutical industry continues to break new ground, redefining treatment innovation, market access, and the role of technology in healthcare. In 2024, we witnessed a wave of transformative advancements that reshaped the landscape. Staying ahead of these trends is vital for fostering innovation, navigating challenges, and seizing new opportunities.  To honor the milestones of 2024,

For over 70 years, patients with classic congenital adrenal hyperplasia (CAH) have had limited treatment options—options that often come with debilitating side effects. However, a new chapter begins with the recent FDA approval of Neurocrine Biosciences’ Crenessity, the first non-steroidal treatment for CAH. This decision heralds a groundbreaking shift in the management of this rare

Healthcare is entering an era of profound transformation, and personalized medicine stands at its forefront. This shift has not only reshaped clinical approaches but has also expanded into patient support systems. For market access and patient services teams, predictive analytics and artificial intelligence (AI) offer opportunities to revolutionize how we assist patients. By leveraging powerful